Recurrent and Metastatic Head and Neck Cancers
Publication Date: December 14, 2022
Key Points
Key Points
- Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
- Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
- The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.
Treatment
...reatment
...1.1Programmed death-ligand 1 (PD-L1) immunohist...
...dation 1.2PD-L1 combined positive score (CP...
Recommendation 1.3Tumor mutational burden (TMB)...
...ation 1.4TMB ≥10 should be interpreted a...
...ion 2.1Pembrolizumab monotherapy or pe...
...tion 2.2Pembrolizumab, platinum, and 5-FU may be...
...3.1Pembrolizumab or nivolumab should...
...ndation 4.1Toripalimab, camrelizumab...
...n 4.2Programmed cell death protein 1 (PD-1...
...ation 5.1For patients with oligometastatic HNSC...
...n 6.1Pembrolizumab may be offered to patient...
...on 6.2Pembrolizumab may be offered to patients w...
...1. Biomarkers and Recommendations by PD-L1 Status...
...gure 2. Recommendations by Subtype...